SecBot SecBot
Insider Cluster (1 insider) ·Filed Mar 10, 2026

BBIO

BridgeBio Pharma, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed8mo ago
Insider cluster: 2 insiders, $1.3M total
Actionable Insight • Neutral

The sale is minor relative to company size and likely routine; monitor for additional sales or participation from other insiders to assess potential concern.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$74.32
T+0 close · Mar 9, 2026 · via day close
Latest settled
−11.89%
T+60 · $65.48
Vs SPY
−23.30%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 10 $74.32entry
  2. T+1 · 8mo ago −3.94%α −3.84% · $71.39
  3. T+5 · 8mo ago −4.55%α −3.64% · $70.94
  4. T+20 · 7mo ago −0.24%α −0.09% · $74.14
  5. T+60 · 6mo ago −11.89%α −23.30% · $65.48
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BridgeBio Pharma CEO Kumar Neil was granted a total of 144,883 shares in non-cash awards and sold 9,690 shares in an open-market transaction worth approximately $662,441. The sale represents a small fraction of the company's market cap and is likely part of a pre-arranged trading plan.

Key Financial Metrics

Direction
selling
Total Value
$662.4K
Insiders
1

Key Facts

  • CEO Kumar Neil received two non-cash stock awards totaling 144,883 shares with no economic value at grant.
  • CEO sold 9,690 shares in an open-market transaction at $68.3634 per share, totaling $662,441.
  • Total value of open-market sale is $662,441, representing approximately 0.0049% of BBIO's $13.6B market cap.

Financial Impact

$662,441 in open-market sales; no financial impact from non-cash grants

insider ownershipshare count (dilution from grants)

Risk Factors

  • Non-cash grants may lead to future dilution, though standard for executive compensation.
  • Single insider sale, even if small, could signal reduced conviction if followed by further selling.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CONTEXT: Insider Cluster Data (3 trades, 7d window)cluster-BBIO-1773952120485

Track record

38 reports on BBIO

Performance horizon

10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $78.30 +0.17% settles Dec 11
  2. Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  3. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  4. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  5. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $78.30 +4.47% settles Nov 30
  6. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $78.30 +10.56% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $78.30 +14.94% settles Nov 19
  8. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $78.30 +23.70% ▲ +24.28% +27.89% vs SPY
  9. Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
  10. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (13h 16m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 19, 2026